메뉴 건너뛰기
European Journal of Dermatology
Volumn 26, Issue 3, 2016, Pages 320-321
A case of drug-associated dermatomyositis following ipilimumab therapy
Author keywords

[No Author keywords available]
Indexed keywords

EID: 85032447026     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2016.2770     Document Type: Article
Times cited : (27)
References (9)
  • 1
    • 84890417671 scopus 로고    scopus 로고
    • Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
    • Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatol Treat 2014; 25: 401–8. DOI: 10.3109/09546634.2013.813897
    • (2014) J Dermatol Treat , vol.25 , pp. 401-408
    • Ma, C.1    Armstrong, A.W.2
  • 2
    • 84969141445 scopus 로고    scopus 로고
    • Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
    • COI: 1:CAS:528:DC%2BC2MXntFOrurg%3D
    • Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2015; 3: 1–7.
    • (2015) JAMA Oncol , vol.3 , pp. 1-7
    • Johnson, D.B.1    Sullivan, R.J.2    Ott, P.A.3
  • 3
    • 84922945447 scopus 로고    scopus 로고
    • Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade
    • Sheik AS, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015; 151: 195–9. DOI: 10.1001/jamadermatol.2014.2233
    • (2015) JAMA Dermatol , vol.151 , pp. 195-199
    • Sheik, A.S.1    Goddard, A.L.2    Luke, J.J.3
  • 4
    • 0037339920 scopus 로고    scopus 로고
    • Hydroxyurea-induced dermatomyositis-like eruption
    • PID: 12637927
    • Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol 2003; 48: 439–41. DOI: 10.1067/mjd.2003.74
    • (2003) J Am Acad Dermatol , vol.48 , pp. 439-441
    • Dacey, M.J.1    Callen, J.P.2
  • 5
    • 0018613786 scopus 로고
    • Dermatomyositis induced by penicillamine
    • COI: 1:STN:280:DyaL3c7kvF2mtQ%3D%3D, PID: 94219
    • Simpson NB, Golding JR. Dermatomyositis induced by penicillamine. Acta Derm Venereol 1979; 59: 543–4.
    • (1979) Acta Derm Venereol , vol.59 , pp. 543-544
    • Simpson, N.B.1    Golding, J.R.2
  • 6
    • 67649908730 scopus 로고    scopus 로고
    • Simvastatin-induced amyopathic dermatomyositis
    • COI: 1:STN:280:DC%2BD1Mvnt1elsQ%3D%3D, PID: 19438466
    • Inhoff O, Petitsch WK, Paredes BE, Goerdt S, Goebeler M. Simvastatin-induced amyopathic dermatomyositis. Br J Dermatol 2009; 161: 206–8. DOI: 10.1111/j.1365-2133.2009.09205.x
    • (2009) Br J Dermatol , vol.161 , pp. 206-208
    • Inhoff, O.1    Petitsch, W.K.2    Paredes, B.E.3    Goerdt, S.4    Goebeler, M.5
  • 7
    • 84855397150 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor inhibitor therapyinduced dermatomyositis and fasciitis
    • PID: 22210682
    • Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapyinduced dermatomyositis and fasciitis. J Rheumatol 2012; 39: 192–4.
    • (2012) J Rheumatol , vol.39 , pp. 192-194
    • Riolo, G.1    Towheed, T.E.2
  • 8
    • 33845643709 scopus 로고    scopus 로고
    • Cytomegalovirus infection complicating immunosuppressive therapy for dermatomyositis
    • PID: 17106602
    • Hashimoto A, Okuyama R, Watanabe H, Tagami H, Aiba S. Cytomegalovirus infection complicating immunosuppressive therapy for dermatomyositis. Acta Derm Venereol 2006; 86: 535–7. DOI: 10.2340/00015555-0152
    • (2006) Acta Derm Venereol , vol.86 , pp. 535-537
    • Hashimoto, A.1    Okuyama, R.2    Watanabe, H.3    Tagami, H.4    Aiba, S.5
  • 9
    • 84886802891 scopus 로고    scopus 로고
    • Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1β
    • COI: 1:CAS:528:DC%2BC3sXhslSqu77N, PID: 24037894
    • Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1β. Arthritis Rheum 2013; 65: 2954–62. DOI: 10.1002/art.38093
    • (2013) Arthritis Rheum , vol.65 , pp. 2954-2962
    • Fiorentino, D.F.1    Chung, L.S.2    Christopher-Stine, L.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.